{"database": "openregs", "table": "documents", "is_view": false, "human_description_en": "where agency_id = \"FDA\" and docket_id = \"FDA-2016-N-3464\" sorted by posted_date descending", "rows": [["FDA-2016-N-3464-0029", "FDA", "FDA-2016-N-3464", "List of Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act", "Rule", "Final Rule", "2019-02-19T05:00:00Z", 2019, 2, "2019-02-19T05:00:00Z", null, "2019-02-19T14:46:18Z", "2019-02367", 0, 0, "0900006483a88bb0"], ["FDA-2016-N-3464-0033", "FDA", "FDA-2016-N-3464", "Reference 16 - Food and Drug Administration Supplemental Review of Topical Tranilast, April 25, 2016.", "Supporting & Related Material", "Background Material", "2019-02-19T05:00:00Z", 2019, 2, null, null, "2019-02-19T19:50:14Z", null, 0, 0, "0900006483a8baf0"], ["FDA-2016-N-3464-0030", "FDA", "FDA-2016-N-3464", "Reference 3 - Memorandum to File on Food and Drug Administration Consultations with United States Pharmacopeia, September\n26, 2016.", "Supporting & Related Material", "Background Material", "2019-02-19T05:00:00Z", 2019, 2, null, null, "2019-02-19T19:44:10Z", null, 0, 0, "0900006483a8baed"], ["FDA-2016-N-3464-0031", "FDA", "FDA-2016-N-3464", "Reference 4 - Letter from the United States Pharmacopeia to FDA, October 7, 2016.", "Supporting & Related Material", "Background Material", "2019-02-19T05:00:00Z", 2019, 2, null, null, "2019-02-19T19:46:13Z", null, 0, 0, "0900006483a8baee"], ["FDA-2016-N-3464-0032", "FDA", "FDA-2016-N-3464", "Reference 10 - Food and Drug Administration Supplemental Review of Oxitriptan, November 2018.", "Supporting & Related Material", "Background Material", "2019-02-19T05:00:00Z", 2019, 2, null, null, "2019-02-19T19:48:01Z", null, 0, 0, "0900006483a8baef"], ["FDA-2016-N-3464-0005", "FDA", "FDA-2016-N-3464", "Reference 3 - FDA, Transcript of the February 24, 2015, Meeting of the Pharmacy Compounding Advisory Committee, 2015", "Supporting & Related Material", "Background Material", "2016-12-16T05:00:00Z", 2016, 12, null, null, "2016-12-16T16:12:35Z", null, 0, 0, "0900006482415bee"], ["FDA-2016-N-3464-0008", "FDA", "FDA-2016-N-3464", "Reference 6 - Letter from USP to FDA, October 7, 2016", "Supporting & Related Material", "Background Material", "2016-12-16T05:00:00Z", 2016, 12, null, null, "2016-12-16T16:12:45Z", null, 0, 0, "0900006482415e69"], ["FDA-2016-N-3464-0004", "FDA", "FDA-2016-N-3464", "Reference 2 - FDA, Transcript of the February 23, 2015, Meeting of the Pharmacy Compounding Advisory Committee (Afternoon Session), 2015", "Supporting & Related Material", "Background Material", "2016-12-16T05:00:00Z", 2016, 12, null, null, "2016-12-16T16:12:31Z", null, 0, 0, "0900006482415bed"], ["FDA-2016-N-3464-0007", "FDA", "FDA-2016-N-3464", "Reference 5 - Memorandum to File on FDA Consultations with USP, September 26, 2016", "Supporting & Related Material", "Background Material", "2016-12-16T05:00:00Z", 2016, 12, null, null, "2016-12-16T16:12:42Z", null, 0, 0, "0900006482415e68"], ["FDA-2016-N-3464-0002", "FDA", "FDA-2016-N-3464", "References List for FDA-2016-N-3464", "Supporting & Related Material", "Background Material", "2016-12-16T05:00:00Z", 2016, 12, null, null, "2016-12-16T16:12:18Z", null, 0, 0, "0900006482415beb"], ["FDA-2016-N-3464-0003", "FDA", "FDA-2016-N-3464", "Reference 1 - Guidance for Industry  Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act", "Supporting & Related Material", "Background Material", "2016-12-16T05:00:00Z", 2016, 12, null, null, "2016-12-16T16:12:27Z", null, 0, 0, "0900006482415bec"], ["FDA-2016-N-3464-0012", "FDA", "FDA-2016-N-3464", "Reference 10 - Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) Trial", "Supporting & Related Material", "Background Material", "2016-12-16T05:00:00Z", 2016, 12, null, null, "2016-12-16T16:12:59Z", null, 0, 0, "0900006482415e6d"], ["FDA-2016-N-3464-0015", "FDA", "FDA-2016-N-3464", "Reference 13 - Case Series  The Effectiveness of Fatty Acids From Pracaxi Oil in a Topical Silicone Base for Scar and Wound Therapy", "Supporting & Related Material", "Background Material", "2016-12-16T05:00:00Z", 2016, 12, null, null, "2016-12-16T16:13:09Z", null, 0, 0, "0900006482415e70"], ["FDA-2016-N-3464-0010", "FDA", "FDA-2016-N-3464", "Reference 8 - FDA Briefing Document for the February 23-24, 2015, Meeting of the Pharmacy Compounding Advisory Committee, 2015", "Supporting & Related Material", "Background Material", "2016-12-16T05:00:00Z", 2016, 12, null, null, "2016-12-16T16:12:52Z", null, 0, 0, "0900006482415e6b"], ["FDA-2016-N-3464-0009", "FDA", "FDA-2016-N-3464", "Reference 7 - FDA Briefing Document for the June 17-18, 2015, Meeting of the Pharmacy Compounding Advisory Committee, 2015", "Supporting & Related Material", "Background Material", "2016-12-16T05:00:00Z", 2016, 12, null, null, "2016-12-16T16:12:49Z", null, 0, 0, "0900006482415e6a"], ["FDA-2016-N-3464-0001", "FDA", "FDA-2016-N-3464", "List of Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act", "Proposed Rule", "Notice of Proposed Rulemaking (NPRM)", "2016-12-16T05:00:00Z", 2016, 12, "2016-12-16T05:00:00Z", "2017-03-17T03:59:59Z", "2017-08-05T01:02:50Z", "2016-30109", 0, 0, "090000648241437d"], ["FDA-2016-N-3464-0011", "FDA", "FDA-2016-N-3464", "Reference 9 - Piracetam in the Treatment of Different Types of Myoclonus", "Supporting & Related Material", "Background Material", "2016-12-16T05:00:00Z", 2016, 12, null, null, "2016-12-16T16:12:56Z", null, 0, 0, "0900006482415e6c"], ["FDA-2016-N-3464-0006", "FDA", "FDA-2016-N-3464", "Reference 4 - Transcript of the June 17, 2015, Meeting of the Pharmacy Compounding Advisory Committee (Afternoon Session), 2015", "Supporting & Related Material", "Background Material", "2016-12-16T05:00:00Z", 2016, 12, null, null, "2016-12-16T16:12:39Z", null, 0, 0, "0900006482415bef"], ["FDA-2016-N-3464-0013", "FDA", "FDA-2016-N-3464", "Reference 11 - FDA Supplemental Review of Topical Tranilast, April 25, 2016", "Supporting & Related Material", "Background Material", "2016-12-16T05:00:00Z", 2016, 12, null, null, "2016-12-16T16:13:02Z", null, 0, 0, "0900006482415e6e"], ["FDA-2016-N-3464-0014", "FDA", "FDA-2016-N-3464", "Reference 12 - Treatment of Keloid and Hypertrophic Scars by Iontophoretic Transdermal Delivery of Tranilast", "Supporting & Related Material", "Background Material", "2016-12-16T05:00:00Z", 2016, 12, null, null, "2016-12-16T16:13:06Z", null, 0, 0, "0900006482415e6f"], ["FDA-2016-N-3464-0016", "FDA", "FDA-2016-N-3464", "Reference 14 - Economic Analysis of Impacts", "Supporting & Related Material", "Background Material", "2016-12-16T05:00:00Z", 2016, 12, null, null, "2017-06-06T19:09:42Z", null, 0, 0, "0900006482415e71"]], "truncated": false, "filtered_table_rows_count": 21, "expanded_columns": [], "expandable_columns": [[{"column": "docket_id", "other_table": "dockets", "other_column": "id"}, "title"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, agency_id, docket_id, title, document_type, subtype, posted_date, posted_year, posted_month, comment_start_date, comment_end_date, last_modified, fr_doc_num, open_for_comment, withdrawn, object_id from documents where \"agency_id\" = :p0 and \"docket_id\" = :p1 order by posted_date desc limit 101", "params": {"p0": "FDA", "p1": "FDA-2016-N-3464"}}, "facet_results": {"agency_id": {"name": "agency_id", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&docket_id=FDA-2016-N-3464", "results": [{"value": "FDA", "label": "FDA", "count": 21, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2016-N-3464", "selected": true}], "truncated": false}, "document_type": {"name": "document_type", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&docket_id=FDA-2016-N-3464", "results": [{"value": "Supporting & Related Material", "label": "Supporting & Related Material", "count": 19, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2016-N-3464&document_type=Supporting+%26+Related+Material", "selected": false}, {"value": "Proposed Rule", "label": "Proposed Rule", "count": 1, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2016-N-3464&document_type=Proposed+Rule", "selected": false}, {"value": "Rule", "label": "Rule", "count": 1, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2016-N-3464&document_type=Rule", "selected": false}], "truncated": false}, "posted_year": {"name": "posted_year", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&docket_id=FDA-2016-N-3464", "results": [{"value": 2016, "label": 2016, "count": 16, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2016-N-3464&posted_year=2016", "selected": false}, {"value": 2019, "label": 2019, "count": 5, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2016-N-3464&posted_year=2019", "selected": false}], "truncated": false}}, "suggested_facets": [{"name": "title", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2016-N-3464&_facet=title"}, {"name": "subtype", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2016-N-3464&_facet=subtype"}, {"name": "posted_date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2016-N-3464&_facet=posted_date"}, {"name": "posted_month", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2016-N-3464&_facet=posted_month"}, {"name": "posted_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2016-N-3464&_facet_date=posted_date"}, {"name": "comment_start_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2016-N-3464&_facet_date=comment_start_date"}, {"name": "comment_end_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2016-N-3464&_facet_date=comment_end_date"}, {"name": "last_modified", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-2016-N-3464&_facet_date=last_modified"}], "next": null, "next_url": null, "private": false, "allow_execute_sql": true, "query_ms": 502.4103739997372, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}